Overactive Bladder - Results from #120

REVIEW UroToday

The Impact of an Overactive Bladder Care Pathway on Longitudinal Patient Management. March 17, 2024

Multicomponent Intervention for Overactive Bladder in Women: A Randomized Clinical Trial. March 14, 2024

Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. March 10, 2024

Radiofrequency as the New Opportunity in Treating Overactive Bladder and Urge Urinary Incontinence-A Single-Arm Pilot Study. March 10, 2024

A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder-wet Patients over the Age March 10, 2024

A Discrete Mathematics Approach for Understanding Risk Factors in Overactive Bladder Treatment. March 3, 2024

Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH). March 3, 2024

Job strain, occupation, and bladder health among women March 1, 2024

Need for Public Health Messaging Related to Bladder Health from Adolescence to Advanced Age. March 1, 2024

A positive association between food insecurity and the prevalence of overactive bladder in U.S. adults. February 25, 2024

Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator. February 25, 2024

The Impact of Extracorporeal Magnetic Stimulation as Addition to Mirabegron in Overactive Bladder Treatment in Women: A Single-Centre Randomized Sham-Controlled Study. February 18, 2024

Prevalence of overactive bladder among overweight and obese women: A prospective cross-sectional cohort study. February 18, 2024

A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder. February 11, 2024

Microstructural white matter abnormalities in overactive bladder syndrome evaluation with diffusion kurtosis imaging tract-based spatial statistics analysis. February 11, 2024

Concomitant Use of Sodium-Glucose Cotransporter 2 Inhibitors and Overactive Bladder Drugs and the Risk of Urinary Tract Infection. February 11, 2024

Exploring lifelong overactive bladder: Transitions, evidence, and clinical implications; A modified Delphi process. February 4, 2024

Safety and efficacy of an α1 -blocker plus mirabegron compared with an α1 -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: a systematic review and network meta-analysis February 4, 2024

Oxybutynin-Associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment. February 4, 2024

Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists. January 28, 2024

Page 7 of 121